SEC filings
Gilead Sciences (GILD)
Recent filings Gilead Sciences made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000882095All filings on SEC.gov
10-QQuarterly report
Quarterly report
Gilead Sciences reported third-quarter 2026 total revenues of $8.3 billion, up 7% from a year earlier, as HIV product sales rose 18% to $6.2 billion on higher demand and realized prices, including growth in Biktarvy, Descovy and Yeztugo. …
8-KCurrent report
Results of Operations and Financial Condition
Gilead Sciences reported third-quarter 2026 product sales of $8.3 billion, up 13% year over year, and raised its full-year 2026 product sales guidance to $31.0–$31.3 billion from $30.1–$30.4 billion. …
10-QQuarterly report
Quarterly report
Gilead Sciences reported second-quarter 2026 total revenues of $7.8 billion, up 10% from a year earlier, with HIV product sales up 12% to $5.7 billion and COVID-19 antiviral Veklury sales down 81% to $23 million. …
8-KCurrent report
Results of Operations and Financial Condition
Gilead Sciences reported second-quarter 2026 revenues of $7.8 billion, up 10% year over year, while recording a GAAP diluted loss per share of $(8.45) and non-GAAP diluted loss per share of $(6.75), driven by $11.2 billion in acquired…
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Gilead Sciences in Readster
Add Gilead Sciences to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.